GSEP
CRDF icon

Golden State Equity Partners’s Cardiff Oncology CRDF Stock Holding History

Golden State Equity Partners’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.7K Hold
24,500
– – ﹤0.01% 932
2025
Q4 		$68.8K Buy
+24,500
New +$56.9K 0.01% 489

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

Golden State Equity Partners's CRDF Position: Q1 2026 in Review

Golden State Equity Partners held its Cardiff Oncology (CRDF) position steady in Q1 2026 at 24,500 shares worth $39.7K. The position accounts for ﹤0.01% of the portfolio, ranked #932.

Golden State Equity Partners first reported a position in CRDF in Q4 2025 and has held it in 2 quarters since. The position peaked at $68.8K in Q4 2025. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • Golden State Equity Partners held 24,500 shares of Cardiff Oncology worth $39.7K as of Q1 2026.
  • Golden State Equity Partners left its Cardiff Oncology share count unchanged in Q1 2026.
  • Cardiff Oncology made up ﹤0.01% of Golden State Equity Partners's portfolio in Q1 2026, its #932 holding.
  • Golden State Equity Partners first reported a position in Cardiff Oncology in Q4 2025 and has held it in 2 quarters since.
  • Golden State Equity Partners's Cardiff Oncology position peaked at $68.8K in Q4 2025.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Golden State Equity Partners's 13F filing for Q1 2026, filed 28 Apr 2026.